CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg

Compound Name: CJC-1295 (no DAC) + Ipamorelin

Synonyms: CJC-1295 (tetrasubstituted GHRH analog, no DAC), Ipamorelin (GHRP-2 analog)

CAS Number:

• CJC-1295 (no DAC): 863288-34-0
• Ipamorelin: 170851-70-4

Molecular Formula:

• CJC-1295 (no DAC): C₁₅₂H₂₅₂N₄₄O₄₂
• Ipamorelin: C₃₈H₄₉N₉O₅

Molecular Weight:

• CJC-1295 (no DAC): 3367.88 g/mol
• Ipamorelin: 711.86 g/mol

Structure: CJC-1295: Synthetic tetrapeptide; Ipamorelin: synthetic pentapeptide

Peptide Sequence:

• CJC-1295 (no DAC): H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser
• Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Chemical Structure:

CJC-1295:                                                      Ipamorelin:

Source: PubChem                                                      Source: PubChem

Mechanism of Action: The CJC-1295 (no DAC) + ipamorelin peptide blend stimulates endogenous growth hormone (GH) release by simultaneously activating the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin/growth hormone secretagogue receptor (GHSR), resulting in synergistic, physiologically pulsatile GH secretion. This dual-receptor activation enhances circulating IGF-1 levels and supports anabolic and metabolic processes^1-5.

Biological Activity: The CJC-1295 (no DAC) + ipamorelin blend increases circulating growth hormone and IGF-1 levels, promoting anabolic effects, tissue repair, lipolysis, and improved metabolic regulation in research models. This combination mimics natural GH pulsatility while minimizing off-target hormonal activity^1-5.

Storage: Store at -20°C, protect from light.

Drug Categories: GH secretagogues, GHRH analogs, GHSR agonists, research peptides

Additional Notes: For investigational use in laboratory settings only.

Summary Table:

Disclaimer: For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.

Detailed Product Description

The CJC-1295 (no DAC) + Ipamorelin peptide blend is a dual-action investigational formulation developed to study endogenous GH axis modulation. CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH) that activates GHRH receptors in the pituitary, triggering robust and sustained GH secretion via the cAMP/PKA pathway. Ipamorelin (no DAC), a selective ghrelin receptor (GHS-R1a) agonist, induces GH release through calcium-dependent mechanisms without affecting prolactin or cortisol, offering a clean, receptor-specific action profile. Together, these peptides engage distinct but complementary mechanisms to mimic natural GH pulsatility. CJC-1295 initiates a broad GH release, and Ipamorelin (no DAC) enhances and extends this effect by acting on separate signaling pathways. The synergistic stimulation results in increased IGF-1 levels and prolonged anabolic signaling, promoting protein synthesis, lean muscle development, and recovery in research models.

Research Highlights

No peer-reviewed studies published as of June 2025. Information developed based on pharmacology of the individual peptides.

Mechanism of Action

Synergistic Dual-Receptor Activation

• Combined stimulation of GHRH and GHS-R1a receptors leads to amplified and sustained GH release, mimicking natural physiologic pulsatility more effectively than monotherapy. This combination increases both the amplitude and duration of GH secretion, maximizing downstream IGF-1 production and anabolic effects.
• CJC-1295 (no DAC) binds GHRH receptors on pituitary somatotrophs, initiating GH secretion through the cAMP/PKA signaling cascade².
• Ipamorelin selectively targets GHS-R1a, promoting GH release via calcium-mediated pathways^1-5.

Mechanistic Synergy

• Sequential and complementary action: CJC-1295 initiates GH secretion; Ipamorelin prolongs and enhances it.
• Increased IGF-1 levels: Co-administration promotes higher systemic IGF-1, improving muscle protein synthesis, recovery, and lipolysis.
• Preserves natural feedback loops: The physiological stimulation allows for endogenous regulation without suppressing the pituitary axis.
• Reduced desensitization risk: Alternating receptor pathways mitigates receptor fatigue or downregulation seen in monotherapy^1-5.

Pharmacokinetic Profile

• Route of Administration: Subcutaneous Injection

Formulation & Handling

• Supplied as a sterile, lyophilized powder
• Reconstitute with sterile water or buffer as per laboratory protocol
• Store lyophilized at -20°C; reconstituted at 2-8°C for up to 14 days

Selected Clinical Trial Activity

CJC-1295 (No DAC) + Ipamorelin is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. CJC-1295 (No DAC) + Ipamorelin is supplied strictly for laboratory research and investigational purposes only.

References

¹Teichman, S. L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab. 91, 799–805 (2006).

²Raun, K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139, 552–561 (1998).

³Svensson, J. et al. Ipamorelin, a new growth hormone releasing peptide, induces muscle growth by stimulating GH release in rats. Am. J. Physiol. Endocrinol. Metab. 275, E123–E129 (1998).

⁴Ghigo, E., Arvat, E., Muccioli, G. & Camanni, F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 136, 445–460 (1997).

⁵Smith, R. G. et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 18, 621–645 (1997).